Efficacy and safety of first-line durvalumab (D) ± tremelimumab (T) vs platinum-based chemotherapy (CT) based on clinical characteristics in patients with metastatic (m) NSCLC: Results from MYSTIC
Titel:
Efficacy and safety of first-line durvalumab (D) ± tremelimumab (T) vs platinum-based chemotherapy (CT) based on clinical characteristics in patients with metastatic (m) NSCLC: Results from MYSTIC
Auteur:
Cho, B.C. Reinmuth, N. Lee, K.H. Ahn, M.-J. Luft, A. Van den Heuvel, M. Dols, M. Cobo Smolin, A. Vicente, D. Moiseyenko, V. Antonia, S.J. Moulec, S. Le Robinet, G. Natale, R. Garon, E.B. Nakagawa, K. Liu, F. Thiyagarajah, P. Peters, S. Rizvi, N.A.